

Immunosuppressive Treatment in Antiphospholipid Sy

Biomedicines

9, 132

DOI: [10.3390/biomedicines9020132](https://doi.org/10.3390/biomedicines9020132)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. <i>Paediatric Drugs</i> , 2022, 24, 13-27.	3.1	5
2	Preliminary Study on the Imbalance Between Th17 and Regulatory T Cells in Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
3	Disability and cognitive impairment are interdependent in primary antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 1104-1113.	1.6	2
4	The challenges in diagnosing pediatric primary antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 1269-1275.	1.6	4
5	Antisynthetase syndrome with rare <sc>EJ</sc> antibodies with antiphospholipid syndrome. <i>Respirology Case Reports</i> , 2022, 10, .	0.6	0
6	B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy?. <i>Journal of Clinical Medicine</i> , 2023, 12, 18.	2.4	7
7	A20 haploinsufficiency caused by loss of function <i>TNFAIP3</i> mutation likely leads to progression of antiphospholipid syndrome to marginal zone lymphomas following coronavirus disease 2019 vaccination: A case study. <i>Clinical and Translational Discovery</i> , 2023, 3, .	0.5	0
8	An Antiphospholipid Antibody Profile as a Biomarker for Thrombophilia in Systemic Lupus Erythematosus. <i>Biomolecules</i> , 2023, 13, 617.	4.0	1
9	Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	8
10	Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades. <i>Biomedicine</i> , 2023, 11, 1218.	3.2	2
11	Calcinosis Cutis and Calciphylaxis in Autoimmune Connective Tissue Diseases. <i>Vaccines</i> , 2023, 11, 898.	4.4	5